

## SUNDAY, 24 AUGUST 2003

### Poster Session C

*Poster Setup Time: 7:00am-8:00am*

*Poster Presentation Time: 12:00pm - 1:30pm*

- 1 **Armagnac Versus Vodka: Effects on Platelet Aggregation in a Randomised Clinical Trial [313]**  
Anwar Umar, Fanny Depont, Alain Jacquet, Severine Lignot, Bernard Begaud, Marie Claude Segur, Michel Boisseau, Nicholas Moore. (France)
- 2 **Sertindole Versus Risperidone Outcome Study: An Innovative Pharmacovigilance Study (I) [316]**  
Aurelia Mittoux, Jozef Peuskens, Mogens Sloth-Nielsen, Ronald Mann, Nicholas Moore. (France)
- 3 **Self-Purchasing of Antibiotics in a Developing Country – India [312]**  
Bhagirath Keshavlal Patel, Ramesh K Goyal. (India)
- 4 **Feedback Intervention to Physicians and Pharmacists To Improve Medication Use in Asthma Care: Methods and Preliminary Results [314]**  
Regis Blais, Claudine Laurier. (Canada)
- 5 **Pragmatic Randomized Clinical Trial for Treatment with Inhibitors of Cyclo-Oxygenase in Patients with Osteoarthritis: The Practice Study [315]**  
Georgio Mosis, Jeanne P Dieleman, Johan vd Lei, Bruno HCH Stricker, Sturkenboom CJM Sturkenboom. (Netherlands)
- 6 **Failure To Validate Pneumococcal Pneumonia Diagnoses in the General Practice Research Database [324]**  
Joshua P Metlay, Judith L Kinman. (United States)
- 7 **Ethnic Differences in the Utility of a Primary Care Panic Screening Instrument [327]**  
Abraham G Hartzema, Michael R Johnson. (United States)
- 8 **Retained Menstrual Tampons: Hazards and Epidemiology [323]**  
Roselie A Bright, Diane E Dwyer. (United States)
- 9 **Determining Consumer Preferences for Increased Regulation of Natural Health Products (NHPs) [325]**  
Ola Norrie, Colleen J Metge. (Canada)
- 10 **Withdrawn**
- 11 **Brazilian International Recall Monitoring Project [321]**  
Flavia Q Leite, Murilo F Dias, Nair R Souza, Gilvania M Pinto, Elenice Lacerda, Patricia M Figueiredo. (Brazil)
- 12 **Immoderate Exposure to the Sun : Short-Term Impact on Quality of Life [317]**  
Charles Taieb, Eric Myon. (France)
- 13 **Measuring Disability in Stroke Outcomes Research. The Clinical Meaning of the Barthel Index, the Functional Independence Measure, and the Modified Rankin Scale [326]**  
Sooyeon Kwon, Abraham G Hartzema, Pamela W Duncan, Sue Min Lai. (United States)
- 14 **Early Estimation of Excess Risk of Serious Cutaneous Reactions for Newly Marketed Drugs [328]**  
Alejandro Arana, Jordi Castellsague, Fabio Trave, Susana Perez Guthmann, Kenneth Rothmann, Felix Arellano. (Spain)

- 15 **Does Primary Non-Compliance Reduce the Validity of Pharmacy Data in the Netherlands? [318]**  
Hilde Tobi, Nico-Jan N van den Heuvel, Lolkje TW de Jong-van den Berg. (Netherlands)
- 16 **Accuracy of Days Supply vs. Pills Dispensed in Medicaid Data [319]**  
Robert Gross, Warren Bilker, Sean Hennessy, John Farrar, Brian Strom. (United States)
- 17 **Compliance in the Elderly: Agreement Between Self-Report and Pharmacy Records [320]**  
Line Guenette, Jocelyne Moisan, Michel Preville, Richard Boyer. (Canada)
- 18 **FDA Adverse Event Reports on the Use of Sibutramine: An Exploratory Analysis [329]**  
Marcus M Stavchansky, James P Wilson. (United States)
- 19 **Initial Antibiotic Utilization in Emergency Room Patients diagnosed with Pneumonia and the Effect on Return Rate [337]**  
Stephen P Motsko, Adele Henneke, Terri Conner. (United States)
- 20 **Risk of Cardiovascular Diseases in Patients Using Atypical Antipsychotic Drugs: A Risk Assessment Tool [341]**  
Amir Abbas Tahami Monfared, Delphine Gueylard Chenevier, Benedicte Lescauwae, Jacques LeLorier. (Canada)
- 21 **Clinical and Economic Consequences of Drug Formulary Restrictions: A Direct Comparison of Randomized vs. Observational Evidence [331]**  
Sebastian Schneeweiss, Malcolm Maclure, Robert J Glynn, Bruce Carleton, Jerry Avorn. (United States)
- 22 **Grouping Drug-Related Problems for Failure Analysis [333]**  
Steven L Clause, Darren M Triller. (United States)
- 23 **The Validity of a Questionnaire on Medicines Used in Health Care Practice - - Comparison of a Questionnaire and Computerized Medical Record Survey [330]**  
Ahmad Al-Windi. (Sweden)
- 24 **Outcome-Based Evaluation of a Method for Obtaining U.S. National Estimates of Inpatient Drug Utilization [344]**  
Judy A Staffa, Ben Gutierrez, Cynthia Kornegay, Angela Blount, Marilyn Pitts, David J Graham, Parivash Nourjah, Yi Tsong. (United States)
- 25 **Comparison of Pulmonary Adverse Drug Reactions in Patients Treated with Gemcitabine and a Combination of Gemcitabine and a Taxane for Different Cancers [343]**  
Jean Kilgour-Christie, Andrzej Czarnecki. (United Kingdom)
- 26 **Rapid Data-Mining Analysis of All Recorded Comorbidities Comparing Persons with a Selected Condition and a Control Group. An Example: The Restless Legs Syndrome [332]**  
Hans Petri, Steven J Barrett, Tim Sampson. (United Kingdom)
- 27 **Proportional Reporting Ratios for Signal Detection in the Drug Safety Database of a Pharmaceutical Company [340]**  
Markus Follmann, Alexander Michel. (Germany)
- 28 **The Slone Drug Dictionary: A Research Driven Pharmacoepidemiology Tool [334]**  
Katherine E Kelley, Thomas P Kelley, David W Kaufman, Allen A Mitchell. (United States)
- 29 **Withdrawn**
- 30 **New Drugs in Brazil in the Globalization Era: Comparison between the Brazilian Market with the American and European from 1998 to 2002 [336]**

Carlos CF Vidotti, Marcus Tolentino, Rogério Hoefler, Emília V Silva, Ana Paula P Lima, Lia LC Castro. (Brazil)

- 31 **Comparison of Methodologies for Signal Detection Using Japanese Spontaneous Reports [335]**  
Eri Kawabe, Tsugumichi Sato, Kiyoshi Kubota. (Japan)
- 32 **Residual Channelling in Non-Experimental Research: Measurement and Control [338]**  
Lise M Bjerre, Jacques LeLorier, Abrahamowicz Michal. (Canada)
- 33 **Issues in the Determination of Disease Prevalence from Medical Record Databases: Cumulative Incidence in Chronic Diseases Such as Gout [342]**  
John T Farrar, Theodore R Mikuls, Kenneth G Saag, Warren Bilker, Shawn Fernandes, Brian L Strom. (United States)
- 34 **Intensive Pharmacovigilance Program of Clozapine in Two Psychiatric Institutions in Bogota D.C. [370]**  
Jairo A Martinez, Jose J Lopez. (South America)
- 35 **Effects of Nonsteroidal Anti-Inflammatory Drugs on Cancer Sites Other Than the Colon and Rectum [350]**  
Antonio Gonzalez-Perez, Luis Alberto Garcia-Rodriguez, Ruy Lopez-Ridaura. (Spain)
- 36 **Over-the-Counter Analgesics Are Safe, Are They Not? [353]**  
Patricia McGettigan, Anne Wilkinson, David Henry. (Australia)
- 37 **A Drug Utilization Analysis of Anti-Arthritic Therapy in Seniors, Nova Scotia Pharmacare Program, 2000-2002 [356]**  
Nicole R Hartnell, Priti S Flanagan, Neil J MacKinnon, Volodko Bakowsky. (Canada)
- 38 **Pharmacoeconomic Evaluation of Oseltamivir in Preventing Influenza in Japan [358]**  
Shunya Ikeda, Hiroyuki Sakamaki, Naoki Ikegami. (Japan)
- 39 **Can Fexofenadine Cause Heart Rhythm Disorders? [365]**  
Marie Lindquist, Monica E Pettersson, I Ralph Edwards. (Sweden)
- 40 **Stevens Johnson Syndrome & Toxic Epidermal Necrolysis with COX-2 Inhibitors [348]**  
Lois A La Grenade, Joyce Weaver, Renan A Bonnel, Claudia B Karwoski, Allen D Brinker, Lauren Lee. (United States)
- 41 **Ditropan XL Versus Detrol in Patients Previously Treated with Antimuscarinic Agents: A Canadian Economic Analysis [346]**  
Denis Getsios, J Jaime Caro, Wissam El-Hadi, Krista Payne. (United States)
- 42 **A Survey To Examine Physicians' Understanding of the Incremental Cost Per Quality Adjusted Life Year (Cost/QALY) and Its Effect on Resource Allocation Decision-Making [349]**  
Laveena T Kamboj, Mitchell AH Levine. (Canada)
- 43 **Gastroesophageal Reflux in Infants: Impact on the QOL of Parents [345]**  
Charles Taieb, Eric Myon. (France)
- 44 **Safety Profile Analysis of Liver Disorders in Patients Treated with Celecoxib and Rofecoxib [366]**  
David Sanchez Matienzo, Victoria Gimeno, Jordi Castellsague, Alejandro Arana. (Spain)
- 45 **Determinants of Discontinuation of Initial Highly Active Antiretroviral Therapy(HAART) Regimens in a US HIV Patient Cohort [351]**  
Yong Yuan, Uchenna Iloeje, Gilbert L'italien. (United States)

- 46 **An Educational Intervention Directed at Healthcare Providers and Patients Improves Attention to Osteoporosis in the Fracture Patient [354]**  
Christine Simonelli, Julie A Morancey, Kathleen K Killeen, Leah Swanson, Terrance J Gioe, Ya-Ting Chen, Thomas W Weiss. (United States)
- 47 **Danish General Practitioners' Assessment of Quality Indicators for Prescribing. A Delphi Study [355]**  
Hanne MS Rasmussen, Jens Soendergaard, Jens P Kampmann, Morten Andersen. (Denmark)
- 48 **Charting Trends in the Usage of Statins [360]**  
Yoon J Kong, Laura A Governale, Judy A Staffa, Jennie Chang. (United States)
- 49 **Pharmaceutical Care: Effects, Attitudes and Barriers [364]**  
Jens Sondergaard, David Gaist, Morten Andersen. (Denmark)
- 50 **Use of Novel Methodology for a Risk Management Program Examining Risk of Abacavir Hypersensitivity Reaction, Rechallenge Reaction, Hospitalization, and Death [362]**  
David C Gibbons, Rose K Baker, John A Bartlett, Amy G Cutrell, Joseph J Eron, Jr, Gregory P Fusco, Jennifer S Fusco, Joel E Gallant, Beth L Nordstrom, Larry Mole, Richard D Moore, Daniel M Rosenberg, Alexander M Walker, Alice D White, Kathleen C Wood. (United States)
- 51 **Database Using Post-Marketing Surveillance Data [347]**  
Toshiharu Fujita, Yoshihiko Miura, Takeshi Myama. (Japan)
- 52 **Risk Sharing in a State Funded Health Service: Outcomes Guarantee Project [352]**  
Stephen Chapman, Elly Reeve. (United Kingdom)
- 53 **Clinical Outcomes and Persistence on Glaucoma Therapy: Results from a Canadian Chart Review [357]**  
L Bernard, J Gohill, K Verstraten, M Kirker, A Lam, B Miller, H Conway, DG Grima. (Canada)
- 54 **Safety Profile Analysis of Smell and Taste Disorders in Patients Treated with COX-2 Specific Inhibitors and Other Selected Drugs [359]**  
David Sanchez Matienzo, Victoria Gimeno, Jordi Castellsague, Alejandro Arana. (Spain)
- 55 **A Survey of Pharmacy Students' Exposure to Adverse Event Collection System in the Pharmaceutical Industry [361]**  
Dawn Boberick, Anthony G Oladipo, Isaac W Hammond. (United States)
- 56 **Evaluation of Data Mining Methods in Pharmacovigilance Using Simulated Datasets [363]**  
Emmanuel Roux, Pascale Tubert-Bitter, Frantz Thiessard, Annie Fourier, Bernard Bégau. (France, Metropolitan)
- 57 **A Comparative Safety Profile of Serious Skin and Hypersensitivity Reactions: COX-2 Specific Inhibitors vs. Non-Selective NSAIDs and Other Selected Drugs [367]**  
David Sanchez Matienzo, Victoria Gimeno, Jordi Castellsague, Alejandro Arana. (Spain)
- 58 **Pregnancy Outcome and Maternal Changes in Smoking Habit's with Gestational Exposure to Bupropion [371]**  
Adrienne Einarson, Brian Chan, Peter Selby, Sharon Voyer-Lavigne, Gideon Koren. (Canada)
- 59 **Data Mining for Signal Detection: If, When and How Should Stratification Be Performed? [368]**  
Andrew Bate, Ralph I Edwards, Marie Lindquist, Roland Orre. (Sweden)
- 60 **Withdrawn**